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1 Drug description 
Generic/Brand name/ATC code:  
Dasatinib/Sprycel®/ L01XE06 
Developer/Company: 
Bristol-Myers Squibb 
Description:  
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) targeting 
the BCR-ABL tyrosine kinase protein. [1]. BCR-ABL is the oncogenic 
product of the Philadelphia chromosome, which is present in >90% of 
cancer cells of all adult patients suffering from chronic myeloid leukaemia 
(CML). The BCR-ABL fusion protein acts as a tyrosine kinase inhibitor 
(TKI) mediating the development and maintenance of CML through 
interaction with multiple downstream signalling partners, resulting in 
altered cellular adhesion, activation of mitogenic signalling and inhibition 
of apoptosis. This leads to the transformation of hematopoietic stem cells. 
Briefly, TKIs have the ability to significantly reduce the proliferation of 
BCR-ABL positive CML cells by inhibiting the BCR-ABL pathway [2]. 
Further, dasatinib also inhibits other tyrosine kinases, including Src family 
kinases, c-Kit, EPH receptor A2, and platelet-derived growth factor receptor 
(PDGFR)-β [3-4]. 
The current standard of care in patients with CML is imatinib therapy. 
Despite high response rates of CML patients to imatinib, many patients 
require alternative treatment options (e.g. second-generation TKIs like 
dasatinib or nilotinib) [3].  
The recommended dose for the treatment of chronic phase CML patients is 
dasatinib 100mg administered orally once daily. The treatment of CML 
patients with dasatinib is continued until disease progression or 
unacceptable toxicity in clinical trials [5]. 
2 Indication 
Dasatinib is indicated for the 1st-line treatment of adult patients with 
Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia 
(CML) in the chronic phase (CP) (Ph+ CML-CP). 
3 Current regulatory status 
The European Medicines Agency (EMA) granted orphan drug designation 
to dasatinib (Sprycel®) for the treatment of CML in December 2005. Since 
2006 dasatinib is approved for the treatment of adults with chronic, 
accelerated or blast phase CML with resistance or intolerance to prior 
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therapy including imatinib mesylate and for the treatment of adults with 
Ph+ acute lymphoblastic leukaemia (Ph+ALL) and lymphoid blast CML 
with resistance or intolerance to prior therapy [6]. 
In October 2010, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion to recommend dasatinib for the 
treatment of newly diagnosed Ph+ CML-CP patients [7], which was 
confirmed by the European Commission in December 2010 [8]. 
The US Food and Drug Administration (US FDA) initially approved 
dasatinib for the treatment of adults with CML with resistance or 
intolerance to prior therapy including imatinib and for the treatment of 
adults with Ph+ ALL with resistance or intolerance to prior therapy in 2006 
[9]. 
As EMA, the US FDA granted accelerated approval of dasatinib for the 1st-
line treatment of newly diagnosed adults with CML in the chronic phase in 
October 2010. The US FDA approved dasatinib within this indication under 
the condition that the Marketing Authorisation Holder will present follow-
up data of the current phase III trial NCT00481247 as specified in the study 
protocol – until 2014 [10]. 
4 Burden of disease 
CML is a clonal haematopoietic stem-cell disorder resulting in a 
dysregulated production and uncontrolled proliferation of mature and 
maturing granulocytes (i.e. white blood cells) [11]. CML is one of the few 
malignant diseases triggered by a single oncogene – the BCR-ABL fusion 
protein, which acts as an active kinase. Thus, kinase inhibitors such as 
imatinib, nilotinib and dasatinib are efficacious in the CML-CP therapy by 
blocking the activity of BCR-ABL [12]. CML is initially diagnosed by 
typical findings in the blood and in the bone marrow. Blood tests at 
diagnosis include a complete blood count with microscopic differential 
count, assessment of BCR-ABL mRNA transcripts, cytogenetic analysis and 
HLA-typing [13]. Investigations for the staging of CML include a chest X-
ray, electrocardiogram and echocardiogram, if needed (e.g. when a relevant 
co-existing cardiac disease is suspected). Further, depending on the clinical 
situation and symptoms, a computed tomography, neurologic tests or a 
lumbar puncture may be required. Details about diagnosis and staging are 
described in more detail elsewhere [13-15]. 
CML has basically three different stages – chronic phase, accelerated phase 
and blast crisis. The initial chronic phase (CP) can be asymptomatic and if 
left untreated the disease will progress at random to an accelerated phase 
(AP) and then to fatal blast crisis (BC) within 3 to 5 years [16]. After 2002, 
with the introduction of imatinib as 1st-line therapy in CML, the 5-year 
survival rate improved from 53% (1999-2005) to 89% [16].  
Despite different definitions of accelerated phase and blast crisis, the phase 
of the disease strongly influences the response to therapy, the duration of the 
response and overall survival (OS) with better results for chronic phase than 
for accelerated phase and for accelerated phase than for blast crisis [17]. 
Typical symptoms of CML are fatigue, weight loss, sweating and abdominal 
discomfort from an enlarged spleen [15]. 
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CML accounts for approximately 15-20% of all adult leukaemia patients 
[18-19] with a yearly incidence of 1 in 100,000 of population in Western 
countries [18]. CML is uncommon in children and accounts for less than 5% 
of all childhood leukaemia. Men are generally more often affected than 
women (3:2) and the incidence increases steadily [18] with age. Median age 
is 55-66 years at time of diagnosis [2, 16]. 
Approximately 90-95% of patients are diagnosed in the CP of their disease 
[20] and more than 90% of CML patients are Philadelphia-chromosome 
positive [2]. 
In the treatment management of CML, several prognostic factors have been 
identified, which can be categorised in baseline factors and response-related 
factors. Whereas baseline factors such as phase of the disease and risk scores 
(e.g.: encompassing phase of the disease, blast cell counts, basophils, spleen 
size and cytopenias [13]) can be identified prior to the treatment, response-
related factors like cytogenetic, haematologic and molecular response (CyR, 
HR, MolR) are prognostic factors that can be identified during the 
treatment of CML [17, 21]. As these prognostic factors were established 
based on efficacy data of the 1st-line treatment of CML patients with 
imatinib and recombinant interferon-alpha (rIFNα), the European 
LeukemiaNet [22] points out that these prognostic factors cannot necessarily 
be applied to dasatinib or nilotinib, two second-generation TKIs targeting 
the BCR-ABL fusion gene due to several reasons – short follow-up of 
existing studies and more rapid responses to dasatinib and nilotinib therapy 
compared to imatinib therapy, saying that if a patient has not achieved a 
CyR at 3 months or a less than minor CyR at 6 months, the probability of 
achieving a complete CyR (CCyR) later on is small. Thus, prognostic factors 
regarding the 1st-line therapy in Ph+ CML-CP with dasatinib or nilotinib 
are not yet finally established [22].  
In Austria, the overall incidence of leukaemia was 894 patients, of which 489 
are male and 405 female in 2008 [23]. Applying the above mentioned 
estimates, the incidence of newly diagnosed Ph+ CML-CP patients is 
approximately 110 per year in Austria. 
5 Current treatment 
Since December 2002, imatinib mesylate (IM) at a dose of 400mg once daily 
is approved as 1st-line therapy for CML and is currently considered to be 
standard of care in newly diagnosed CML-CP patients [15, 19, 24]. 
The motivation for treatments other than IM are intolerance or excess 
toxicity, treatment failure, development of BCR-ABL resistant mutations 
and suboptimal response [17]. Therapy options for those patients are: 
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- imatinib dose escalation to 600-800mg/kg, 
- rIFNα, 
- chemotherapeutic drugs such as hydroxyurea, low-dose arabinosyl 
cytosine 
- or allogeneic hematopoietic stem cell transplantation (alloHSCT), 
for those patients who are eligible [15, 25]. 
Though, alloHSCT is considered to be the only possible treatment to cure 
CML, imatinib is still the 1st-line therapy of choice for CML-CP. This is 
because only highly selected patients are eligible for alloHSCT, because of 
the fear of transplant-associated morbidity and mortality and also due to the 
ease of drug administration [12, 26]. An interim safety analysis of the 
randomized German CML Study IV compared the three-year survival 
probability of patients eligible for an alloHSCT (n=53) with matched pairs 
(n=106) not receiving alloHSCT, showing that there was no statistical 
significant difference - alloHSCT: 91.9% (CI 82.9%-97.8%) vs. imatinib-
based drug therapy: 95.9% (CI 91.1% - 98.9%) [26]. 
Despite the positive results of the pivotal imatinib study (IRIS), 18% of 
patients do not achieve a CCyR, approximately 10% of patients who achieve 
CCyR eventually lose their response and 4% to 8% are intolerant to 
imatinib. This results in 30-35% of patients whose outcome with imatinib is 
not optimal [24]. Some population-based series even describe an higher 
necessity for 2nd-line treatments of 51% as presented at the 2010 annual 
meeting of the American Society of Hematology (ASH) [27]. 
Therefore, new strategies for the treatment of imatinib intolerant or 
resistant patients need to be established. Current options for these patients 
are:  
- Higher doses of imatinib, or combination therapy  
- or the use of second-generation TKIs like dasatinib, nilotinib and 
bosutinib [24]. 
In vitro and clinical study results show that these newer TKIs are generally 
more potent inhibitors of BCR-ABL kinase activity and are active against 
most imatinib-resistant tumours harbouring BCR-ABL kinase domain 
mutations. Nilotinib and dasatinib have already demonstrated high efficacy 
with a favourable toxicity profile in CML after failure of imatinib [24]. 
For both new second-generation TKIs, nilotinib and dasatinib, the CHMP 
adopted a positive opinion recommending these new agents for the 1st-line 
treatment of Ph+ CML-CP [7, 28]. 
Within the latest version of the CML clinical practice guideline of the 
National Comprehensive Cancer Network (NCCN) all three TKIs, imatinib, 
nilotinib and dasatinib, are considered to be category 11 treatment options 
for 1st-line therapy of adult patients with Ph+ CML-CP [19]. 
                                                             
1 Category 1 recommendation: based on high-level evidence (i.e., high-powered 
randomized clinical trials or meta-analyses), and the NCCN Guidelines Panel has 
reached uniform consensus that the recommendation is indicated. In this context, 
uniform means near unanimous positive support with some possible neutral 
positions [29] 
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6 Evidence 
In addition to a free text search including the websites of the EMA and the 
US FDA, a systematic literature search was conducted in PubMed, 
EMBASE and the Database of the Center for Review Dissemination 
Database of the National Institute of Health on the 15th of December 2010. 
Search terms included were “dasatinib”, “bms 354825” or “sprycel” for the 
study drug and “chronic myeloid leukemia”, “chronic myelogenous 
leukemia”, “chronic myeloid leukaemia”, “chronic myelogenous leukaemia” 
and CML for the disease.  
447 references were identified of which one phase III trial and one phase II 
trial evaluating the efficacy and safety of dasatinib as 1st-line therapy in 
Ph+CML-CP patients were included. Both studies together investigated 581 
patients. 
The phase III, open-label DASISION trial evaluates the efficacy and safety 
of dasatinib in the 1st-line treatment of adults with Ph+CML-CP. 519 
patients were randomly (1:1) assigned to receive either 100mg dasatinib once 
daily or 400mg imatinib once daily. The confirmed CCyR by 12 months was 
11 percentage points higher among the dasatinib treated patients than the 
imatinib group based on the interim analysis when all patients had a follow-
up of at least 12-months. 
The aim of the phase II study was to assess the safety and efficacy of 
dasatinib as initial therapy in patients with CML in the early chronic phase 
with the primary objective to improve the MMR rate at 12 months from the 
expected 40% based on historical experience with standard-dose imatinib.  
6.1 Efficacy and safety - Phase III study 
Table 1: Summary of efficacy  
Study title  
An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400mg) 
in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic 
Myeloid Leukemia [30-32] 
Study identifier NCT00481247; ATC Code L01XE06; EUDRACT 2006-005712-27, BMS Code: CA180-056 (DASISION) 
Randomized (1:1), open-label, multicenter (108 centres in 26 countries) Design 
Duration  Enrolment: September 2007 - December 2008  
Median follow-up: 14 months (=all patients had a minimum follow-up of 12 
months) 
Cut-off date for primary outcome analysis: December 2009 
Estimated study completion date: January 2014 
Minimum follow-up: 5 years 
Hypothesis Superiority 
Intervention (I) Dasatinib 100mg once daily, orally (with or without food); until disease 
progression or unacceptable toxic effects developed; 259 patients 
Treatment 
groups 
Control (C) Imatinib 400mg once daily, orally (with food); until disease progression or 
unacceptable toxic effects developed; 260 patients 
one phase II and one 
phase III trial identified 
DASISION trial: 
confirmed CCyR by 12 
months +11% 
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Confirmed complete 
cytogenetic response 
by 12 months 
(primary outcome) 
Confirmed 
CCyR 
A CCyR on two consecutive assessments at least 28 days apart. 
Patients who had a first assessment of CCyR at 12 months that 
was confirmed on a second assessment thereafter were 
considered to have had a confirmed CCyR by 12 months 
Complete 
cytogenetic response 
CCyR 0% Ph+ cells in metaphase in the bone marrow 
Time to confirmed 
CCyR 
 Time from randomization to confirmed CCyR 
Rate of CCyR  The proportion of subjects who achieved a CCyR at any time 
from the date of randomization, provided that it is confirmed 
later as described above 
Major molecular 
response  
MMR a BCR-ABL transcript level of 0.1% or lower on the International 
Scale (conversion factor of 0.81), corresponding to a reduction in 
the BCR-ABL transcript level by at least 3-log from the 
standardized baseline level; assessed with the use of a 
quantitative reverse-transcriptase-polymerase-chain-reaction 
(RT-PCR) assay at a centralized laboratory 
Time to a MMR  Time from randomization date to MMR 
Rate of MMR  The proportion of subjects who achieved a MMR at any time 
from the date of randomization 
Progression to the 
accelerated phase or 
blast crisis 
 If any of the following occurred: a doubling of the white-cell 
count to more than 20x109 per litre in the absence of complete 
haematologic response; a loss of complete haematologic 
response; an increase in Ph-positive bone marrow metaphases to 
more than 35%; progression to accelerated phase or blast phase 
CML (details see study protocol [31]); or death from any cause 
Progression-free 
survival 
PFS Time from randomization date until the subject progressed or 
died 
Endpoints and 
definitions 
Overall survival OS From date of randomization to death 
Results and analysis 
Analysis 
description 
Primary analysis: Intention-to-treat analysis 
First interim analysis: all patients had a minimum follow-up of 12 months 
Analysis 
population 
Characteristics: median age I 46 years vs. C 49 years, with I 10% and C 11% of patients being ≥65 
years, male I 56% vs. C 63% ECOG PS 0 or 1: I 100% vs. C 99%, Hasford risk score – low I 33% vs. C 
33%, intermediate I 48% vs. C 47%, high I 19% vs. C 19% 
 
Inclusion: previously untreated patients (≥18 years) with Ph+ CML-CP, ECOG PS 0-2, adequate 
hepatic function (≤2.0 times the institutional upper limit of normal (ULN); alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the institutional ULN); 
adequate organ function (serum creatinine ≤3 times the institutional ULN) 
Exclusion: women who are pregnant or breastfeeding, pleural effusion at baseline, uncontrolled or 
significant cardiovascular disease, history of significant bleeding disorder, prior chemotherapy for 
peripheral stem cell disorder, prior treatment for CML (except anagrelide or hydroxyurea) 
Treatment group I C 
Number of subjects 259 260 
p-value 
Confirmed CCyR by 12 months 
%, (n) 
95% CI 
 
77 (199) 
71 to 82 
 
66 (172) 
60 to 72 
0.007* 
Descriptive 
statistics and 
estimate 
variability 
Confirmed CCyR by 18 months 
%, (n) 
95% CI 
 
78 (n.r.) 
n.r. 
 
70 (n.r.) 
n.r. 
0.0366*** 
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CCyR by 12 months 
%, (n) 
95% CI 
 
83 (216) 
78 to 88 
 
72 (186) 
66 to 77 
0.001* 
MMR at any time 
%, (n) 
95% CI 
 
52 (135) 
46 to 58 
 
34 (88) 
28 to 40 
<0.0001* 
MMR by 12 months 
%, (n) 
95% CI 
 
46 (119) 
40 to 52 
 
28 (73) 
23 to 34 
<0.0001* 
Rates of CCyR by 
3 months, % 
6 months, % 
9 months, % 
 
54 
73 
78 
 
31 
59 
67 
n.r.* 
Rates of MMR by 
3 months, % 
6 months, % 
9 months, % 
 
8 
27 
39 
 
0.4 
8 
18 
n.r.* 
Progression to the accelerated phase or 
blast crisis 
% (n) 
95% CI 
 
 
1.9 (5) 
n.r. 
 
 
3.5 (9) 
n.r. 
n.r.** 
Estimated PFS by 12 months 
% 
95% CI 
 
96 
n.r. 
 
97 
n.r. 
n.r.** 
 Estimated OS by 12 months 
% 
95% CI 
 
97 
n.r. 
 
99 
n.r. 
n.r.** 
 Estimated PFS by 18 months 
% 
95% CI 
 
94.9 
n.r. 
 
93.7 
n.r. 
n.r.*** 
 Estimated OS by 18 months 
% 
95% CI 
 
96.0 
n.r. 
 
97.9 
n.r. 
n.r.*** 
 Comparison groups I vs. C (HR for shorter time to response) 
Hazard ratio (HR) 1.5 
95% CI n.r. 
Time to CCyR was significantly shorter 
with dasatinib than with imatinib 
treatment 
P value  <0.0001** 
HR 2.0 
95% CI n.r. 
Time to MMR was significantly shorter 
with dasatinib than with imatinib 
treatment 
P value  <0.0001** 
HR 1.5 
95% CI n.r. 
Effect estimate 
per comparison 
Time to confirmed CCyR was 
significantly shorter with dasatinib 
than with imatinib treatment 
P value  <0.0001** 
Notes ‐ The provided data are based on a minimum follow-up of 12 months of all patients. A 
minimum 5-year follow-up is planned for the study.  
n.r. – not reported; CI – confidence interval; ECOG PS – Eastern Cooperative Oncology Group performance status 
[33] 
*Cochran-Mantel-Haenzel test stratified by Hasford Score 
**performed using the Kaplan-Meier-product limit method; 95% CI 
***18-months follow-up data presented at the 2010 annual meeting of the American Society of Hematology (ASH) 
[32]. 
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Table 2: Most frequent adverse events 
 Study ID NCT00481247 
Grade (according to 
CTC version 3.0) Outcome 
Intervention 
(n=259) 
Control 
(n=260) 
Haematological 
Neutropenia (%) 65 58 
Thrombocytopenia (%) 70 62 
Anaemia (%) 90 84 
Non-haematological 
Fluid retention (%) 
Superficial edema (%) 
Pleural effusion (%) 
19 
9 
10 
42 
36 
0 
Diarrhoea (%)  17 17 
Nausea (%)  8 20 
Vomiting (%) 5 10 
Myalgia (%) 6 12 
Muscle inflammation (%) 4 17 
Rash (%) 11 17 
Headache (%) 12 10 
All grades 
Fatigue (%) 8 10 
Haematological 
Neutropenia (%) 21 20 
Thrombocytopenia (%) 19 10 
Anaemia (%) 10 7 
Non-haematological 
Fluid retention (%) 1 1 
Diarrhoea (%) <1 1 
Rash (%) 0 1 
Hypophosphatemia (%) 4 21 
Grade ≥3 
QTc interval ≥450msec (%) 2.4 4.4 
 Discontinuation of treatment, 
% (n) 
Drug-related AEs, % (n) 
Death, % (n) 
Treatment failure, % (n) 
 
15.5 (40) 
5 (13) 
1.6 (4) 
2.3 (6) 
 
18.6 (48) 
4.3 (11) 
0.4 (1) 
3.9 (10) 
 
The first interim results of the phase III DASISIONS trial evaluating the 
efficacy and safety of dasatinib as 1st-line treatment of newly diagnosed Ph+ 
CML-CP patients show that the confirmed CCyR by 12 months is 
statistically significant higher in the dasatinib group compared to the 
current standard of care imatinib (I 77% vs. C 66%, p=0.007). Also the rate 
of MMR at 12 months was statistically significant higher in the dasatinib 
group compared to the imatinib group (I 46% vs. 28%, p<0.0001). Whereas 
in the dasatinib group 5 patients (1.9%) progressed to accelerated or blast 
phase, 9 patients (3.5%) in the imatinib group did so. The authors also 
provide estimated rates for PFS and OS at 12 months – PFS is estimated to 
be 96% and 97% for the dasatinib and imatinib group, respectively. The 
estimated rates for OS at 12 months are 97% vs. 99% for the intervention 
first interim results at a 
minimum follow-up of 
12-months of all patients 
randomized 
 
 
equal estimated 12-
months rates of PFS and 
OS 
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and control group, respectively. The safety profile was generally considered 
to be clinically manageable and tolerable. Whereas haematological AEs 
(neutropenia, thrombocytopenia and anaemia) were more frequent and more 
severe (grade ≥3) in the dasatinib group than in the imatinib group, the 
opposite is true for non-haematological AEs. Fluid retention (all grades) 
occurred more frequent in the imatinib group than in the dasatinib group (I 
19% vs. C 42%). The two types of fluid retention reported were superficial 
edema and pleural effusions. Whereas, superficial edema occurred more 
frequent in the imatinib group (I 9% vs. C 36%), pleural effusions were only 
observed in the dasatinib group (I 10% vs. C 0%). 13 patients (5%) in the 
dasatinib group and 11 patients (4.3%) in the imatinib group discontinued 
therapy due to drug-related AEs. 4 (1.6%) and 1 (0.4%) patients 
discontinued therapy due to death in the intervention and control group 
respectively. This study is still ongoing. A follow-up of 5 years is planned. 
Besides, the 18-months follow-up data presentation at the 2010 annual 
meeting of ASH, a safety and efficacy sub-group analysis of patients with 
baseline cardiovascular co-morbidity (85 patients (16%) with ≥ 1 baseline 
cardiovascular condition) was presented. Saglio et al. concluded that though, 
fluid retention and cardiac AEs were more common in patients with baseline 
cardiovascular condition, these data show no substantial impact of baseline 
cardiovascular condition on general safety and efficacy of dasatinib or 
imatinib in the initial treatment of CML-CP [34]. 
6.2 Efficacy and safety - further studies 
Cortes et al. (2010) [35] conducted a phase II study to investigate the safety 
and efficacy of dasatinib as 1st-line therapy in patients with chronic-phase 
CML. The primary objective was to improve the MMR rate at 12 months to 
≥ 40%. 62 patients were randomly allocated to either receive dasatinib 
100mg once daily or 50mg twice daily. 50 patients have been observed for at 
least 3 months and thus the efficacy analysis is based on these fifty patients. 
After a median follow-up of 24 months (range 1 to 39) 41 patients (82%) 
achieved a MMR and 49 patients (98%) achieved a CCyR at any time. There 
was no significant difference in response observed between the two 
treatment arms. The toxicity profile can be divided in haematological and 
non-haematological AEs. Haematological AEs of grade ≥3 are neutropenia 
(21%), thrombocytopenia (10%) and anaemia (6%). The most frequent non-
haematological AEs of grade ≥3 are fatigue (6%), joint and muscle pain 
(6%), peripheral neuropathy (5%), dyspnoea (5%) and memory impairment 
(5%). Again no statistical significant differences between the two study arms 
could be observed regarding frequency and severity of AEs. During the 
study 30 of the 62 patients had treatment interruptions. 5 patients 
discontinued therapy – three because of treatment intolerance, one because 
of patient choice and the other one due to noncompliance. 
 
haematologic AEs were 
more frequent in the 
dasatinib group 
50 pts were evaluable 
for efficacy analysis 
 
at 24 months 98% of 
pts achieved a CCyR 
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7 Estimated costs 
Currently, no official price estimate is available for dasatinib (Sprycel®) in 
Austria. However, the price for one package of Sprycel® including 60 pieces 
of 50mg tablets is € 4,457.- at the Tiroler Landeskrankenanstalten GmbH 
[36]. As stated in chapter 1, the recommended daily dose of dasatinib is 
100mg once daily. Thus, the estimated monthly treatment costs are € 4,457. 
For the current standard of care, imatinib mesylate, the estimated monthly 
treatment costs in Austria are € 2,700.- [37]. Due to expiring patents, these 
costs are expected to drop sharply in the near future. 
Up to date, no data on the median duration of 1st-line dasatinib therapy in 
Ph+CML-CP patients are available yet. As imatinib is able to suppress 
leukemic cell growth for prolonged time periods but cannot eradicate the 
disease, life-long imatinib therapy appears to be required in patients 
responding to the therapy [12]. Considering that dasatinib is able to reduce 
the proliferation of BCR-ABL positive CML cells, but does not cure CML, 
these considerations might also hold true for dasatinib therapy [2]. 
8 Ongoing research 
By searching www.clinicaltrial.gov 2 (search restrictions: dasatinib + phase 
III) 9 phase III trials assessing the efficacy and safety of dasatinib in 
different indications were identified.  
1st-line CML therapy: 
‐ NCT00481247 (DASISION): an open-label, randomized, 
multicenter, phase III trial investigating the efficacy and safety of 
dasatinib compared to imatinib in patients newly diagnosed with 
Ph+ CML-CP. Interim results of this study are presented in 
chapter 6.1. The estimated completion date for the DASISION trial 
is January 2014. 
2nd-line CML therapy: 
‐ NCT00123474: a phase III, randomized two-by-two, multicenter, 
open-label study of dasatinib in patients with Ph+CML-CP or 
BCR-ABL positive CML who are resistant or intolerant to imatinib. 
Dasatinib is studied in four different dosing regimens. The 
estimated study completion date is May 2013. 
‐ NCT00320190: an open-label, randomized phase II/III study of 
dasatinib vs. high-dose imatinib (800mg) in patients suffering from 
CML-CP who have had a suboptimal response after at least 3 
months of therapy with 400mg imatinib. 
‐ NCT00362466: a study comparing the rate of CCyR of dasatinib 
versus high-dose imatinib (600mg) in Ph+CML-CP patients who 
have failed imatinib therapy or who had a suboptimal response 
                                                             
2 ClinicalTrial.gov is a trial registry run by the U.S. National Institutes of Health 
estimated monthly 
treatment costs: € 4,457 
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after 18-months of therapy with 400mg imatinib. This study was 
terminated in 2009 due to insufficient enrolment. 
Further, 5 phase III trials assessing the safety and efficacy of dasatinib for 
the treatment of acute lymphoblastic leukaemia and castration-resistant 
prostate cancer are registered at www.clinicaltrial.gov. One phase III trial 
investigating the safety and efficacy of dasatinib in gastrointestinal stromal 
tumours has been terminated in 2009 based on the recommendation of the 
independent data monitoring committee (IDMC). 
All in all, 162 studies assessing the safety and/or efficacy of dasatinib in 
different indications are registered at ClinicalTrials.gov. Besides different 
types of leukaemia, the effect of dasatinib is investigated in treating patients 
with prostate cancer, breast cancer, glioblastoma, melanoma, pancreatic 
cancer, multiple myeloma, ovarian, peritoneal and tubal cancer, bladder 
cancer myeloproliferative disorders and colorectal cancer [38]. 
9 Commentary 
In October 2010, both regulatory agencies the EMA and the US FDA 
adopted a positive opinion to approve dasatinib for the 1st-line treatment of 
adult patients with Ph+CML-CP. As the results of the pivotal DASISION 
trial submitted for the approval process are first interim results, the 
Marketing Authorisation holder committed to the post-marketing 
requirement to submit long-term follow-up data (at least 60 months of 
follow-up) from the DASISION trial [10]. 
The first interim results of the DASISION study – phase III trial to 
investigate the safety and efficacy as an initial therapy in adults with 
Ph+CML-CP – are presented in chapter 6.1. With a median age of 46 years, 
the study population (n=519) is slightly younger than patients usually are at 
diagnosis. The primary endpoint of this analysis was confirmed CCyR by 12 
months, which was 11 percentage points higher among dasatinib treated 
patients compared to the imatinib group (I 77% vs. C 66%, p=0.007; 18-
months follow-up: difference of 8 percentage points between dasatinib and 
imatinib, p=0.0366). The effect estimate comparisons show that the time to 
confirmed CCyR is shorter for the dasatinib group compared to the imatinib 
treated group (HR 1.5, p<0.0001). Progression to AP or BC was observed in 
5 (1.9%) and in 9 (3.5%) patients in the dasatinib and imatinib groups, 
respectively. The 18-months estimates for PFS are 94.9% vs. 93.7% and for 
OS 96% vs. 97.9% for the dasatinib vs. imatinib groups, respectively. 
Generally the safety profile was considered to be acceptable and clinically 
manageable. Whereas, haematological AEs were more frequent and more 
severe in the dasatinib treated group than in the imatinib treated group, the 
opposite was observed for non-haematological AEs, except pleural effusions, 
which were only observed in dasatinib treated patients [33]. 
Based on the 12- and 18-months interim results the surrogate and primary 
endpoint confirmed CCyR demonstrated superiority of dasatinib over 
imatinib (p=0.007). CCyR was accepted as the primary endpoint by EMA 
and US FDA as the analysis of the pivotal imatinib trial showed that CCyR 
at one year is predictive for PFS. Though, further follow-up is essential to 
show long-term efficacy of dasatinib [6, 10]. 
162 studies registered  
October 2010: approval 
of dasatinib for initial 
therapy of Ph+CML-CP 
interim results of the 
DASISION trial 
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As DASISION trial investigates the safety and efficacy of dasatinib as 1st-
line therapy in Ph+CML-CP patients compared to imatinib, the ENESTnd 
trial compares nilotinib to imatinib. The estimated OS rates at 18-months 
median follow-up are 98.5% and 99.3% for the nilotinib treated groups and 
96.9% for the imatinib treated group. The progression to AP or BC at 12 
months was <1% in the nilotinib groups and 4% in the imatinib group [39]. 
Comparing the interim results of these two studies it cannot be concluded 
which drug is more effective in treating Ph+CML-CP patients.  
The main objective in the treatment of CML patients in the chronic phase is 
to prevent disease progression to accelerated or blast crisis, to reduce the 
number of leukemic cells even if the elimination of the disease cannot be 
achieved [3, 40]. 
With the approval of dasatinib and nilotinib, another second-generation 
TKI targeting the BCR-ABL tyrosine kinase protein, there are now three 
different treatment options available for the 1st-line therapy of CML-CP. 
Both drugs are compared to imatinib in clinical trials. As all three drugs are 
considered to be category 1 (details see chapter 5) treatment options, all 
targeting the BCR-ABL protein, the question for oncologists remain which 
patient to treat with which drug and/or in which sequence these drugs 
should be given [19]. Thus, efficient monitoring is essential to assess the 
efficacy and identify those patients who are responding well and should 
continue the therapy unchanged and those who do not respond and may 
benefit from an alternative treatment option [25].  
Another issue that needs to be pointed out is the treatment costs. Estimated 
monthly treatment costs with dasatinib are around € 4,500 versus € 2,700 for 
one month treatment with imatinib [37], which is about 1.6 times more 
costly than imatinib. Further, the costs of imatinib are expected to drop 
sharply in the near future, due to expiring patents. 
Long-term efficacy and safety of dasatinib and nilotinib as initial therapy in 
Ph+CML-CP patients, the quality of life of the patients, and a head-to-head 
comparison of these two second-generation TKIs are some questions that 
have to be addressed in future trials to improve the treatment of patients 
suffering from CML. 
Despite encouraging data at the interim analyses at 12- and 18-months 
follow-up, mature data on PFS and OS, safety profile and quality of life have 
to be awaited to demonstrate the long-term effectiveness and safety of 
dasatinib as initial therapy in Ph+CML-CP patients. 
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